[The treatment of acromegaly].
Acromegaly is a rare disease which can significantly reduce life expectancy. Clinical features are diverse and the patient may consult a variety of medical and surgical specialists before the diagnosis is suspected. However, the disease is easily confirmed by the appropriate laboratory tests, namely GH and IGF1 measurements. In most cases, acromegaly is secondary to a micro or macrosomatotrope pituitary adenoma. Those lesions are easily visualized by a pituitary CT Scan or Magnetic Resonance Imaging. Visual fields have to be evaluated by a neuro-ophthalmologist, and a thorough evaluation of other pituitary functions have to be performed. Selective removal of the adenoma by the transsphenoidal route is the treatment of choice for acromegaly. When performed by an experienced neurosurgeon, normalization of GH secretion can be expected in approximately 75% of cases. The surgical outcome is modulated by the volume, the extension of the tumor and the preoperative GH level. Octreotide, radiotherapy or bromocriptine are indicated whenever the patient remains with an elevated level of GH with persistency of symptoms.
Beauregard
H
H
Service d'endocrinologie, hôpital Notre-Dame, Université de Montréal, Québec.
Somma
M
M
Rasio
E
E
Serri
O
O
Aris-Jilwan
N
N
Comtois
R
R
Long
H
H
Abribat
T
T
Boucher
A
A
Hardy
J
J
D000172:Acromegaly / Q000209:etiology* / Q000628:therapy*; D000236:Adenoma / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D000465:Algorithms; D001971:Bromocriptine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008279:Magnetic Resonance Imaging; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D014057:Tomography, X-Ray Computed
D001971:Bromocriptine; D013006:Growth Hormone; D015282:Octreotide
Le traitement de l'acromégalie.